Thu, May 1, 10:32 AM (22 days ago)
### Boston Scientific Corporation (BSX) Q1 2025 Financial Summary **Financial Health and Performance:** - **Revenue:** $4.663 billion, up 20.9% YoY. - **Net Income:** $674 million, or $0.45 per diluted share. - **Adjusted Net Income:** $1.121 billion, or $0.75 per diluted share. - **Operating Income:** $921 million. - **Gross Profit Margin:** 68.8%. **Cash Flow:** - **Operating Cash Flow:** $541 million. - **Investing Activities:** -$500 million, including $239 million for the acquisition of Cortex, Inc. - **Financing Activities:** $233 million, including proceeds from the 2025 Eurobonds offering. **Segment Performance:** - **MedSurg:** $1.577 billion, up 11.7% YoY. - **Cardiology:** $2.429 billion, up 29.8% YoY. - **Peripheral Interventions:** $656 million, up 14.4% YoY. **Uncertainties and Future Operations:** - **Economic Environment:** Global supply chain disruptions, inflation, and geopolitical tensions. - **Acquisitions:** Completed acquisition of Cortex, Inc. and pending acquisition of SoniVie Ltd. - **Legal Matters:** Ongoing litigation and regulatory challenges. **Financial Metrics:** - **Debt:** $11.309 billion as of March 31, 2025. - **Cash and Cash Equivalents:** $725 million. - **Leverage Ratio:** 2.21 times as of March 31, 2025. **Trends:** - **Revenue Growth:** Driven by strong commercial execution and acquisitions. - **Profit Margins:** Improved due to higher sales of premium products. - **Cash Flow:** Positive operating cash flow, offset by significant investing activities. **Future Outlook:** - **Growth Initiatives:** Focus on innovation, strategic acquisitions, and global expansion. - **Risk Management:** Addressing supply chain disruptions, inflation, and geopolitical risks. - **Financial Strategy:** Maintaining liquidity, managing debt, and complying with financial covenants.